Using Imiquimod to Treat Lentigo Maligna
Author Information
Author(s): Emma E. Craythorne, C.M. Lawrence
Primary Institution: Dept. of Dermatology, Royal Victoria Infirmary, Newcastle Upon Tyne
Hypothesis
Can imiquimod be an effective treatment for lentigo maligna in patients who cannot undergo surgery?
Conclusion
In 75% of patients treated with imiquimod, the lentigo maligna resolved clinically with no evidence of recurrence after an average follow-up of 34.2 months.
Supporting Evidence
- 75% of patients who developed an inflammatory response to imiquimod were clinically clear of their lentigo maligna.
- Patients were followed for an average of 34.2 months without clinical recurrence.
- The study highlights the importance of an inflammatory response for treatment success.
Takeaway
This study shows that a cream called imiquimod can help clear a type of skin cancer called lentigo maligna in many patients, even if they can't have surgery.
Methodology
Eight patients with difficult-to-treat lentigo maligna were treated with imiquimod for six weeks, applying it daily to the affected area.
Potential Biases
Potential bias due to the small number of patients and lack of control group.
Limitations
The study had a small sample size and lacked histological confirmation of complete clearance in clinically cleared lesions.
Participant Demographics
Average age of participants was 67.25 years, with a mix of recurrent and new cases of lentigo maligna.
Want to read the original?
Access the complete publication on the publisher's website